Navidea Biopharmaceuticals, Inc. (AMEX:NAVB) Q3 2022 Earnings Call Transcript

Michael Rosol: Yes. So there’s all sorts of things going on here. So some of the macrophage markers that represent macrophages that are more anti-inflammatory or wound healing, so those are €“ those are going down in these cells, and with our amino-oncology agents. The ones that are recognized as the pro-inflammatory markers, those are going up. As part of those some markers are going up that interact with T cells to tell the G-cells to attack the tumor cells, and those are going up as well. And then these other things that are involved in what’s called checkpoint inhibition are going down. So we have this concert of different things going on when we introduce our constructs that all work together to rally the body’s immune response, the macrophages and the T cells against the tumors. And we’re seeing all of that in our studies and so, yes, and so that’s €“ it’s just really exciting.

Operator: Thank you. There are no further questions at this time, and I would like to turn the floor back over to Michael for any closing comments.

Michael Rosol: Thank you. I’d like to €“ thank you all for joining us today and for your support of the company and the people here. We will close the call now and see you, I believe at the annual meeting. It will be the next milestone on the calendar. Thank you very much.

Operator: This concludes today’s teleconference. You may now disconnect your lines at this time. Thank you for your participation and have a great day.